AX-2024-004791
SS-31 (Elamipretide) · 20 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2410-K5866
- Report ID
- AX-2024-004791
- Compound
- SS-31 (Elamipretide)
- Compound class
- Metabolic and mitochondrial peptides
- Supplier
- Homopeptide — Hunan Aslsen Technology Co., Ltd.
- Batch / lot
- HOMO-2410-K5866
- Declared label claim
- 20mg
- Laboratory
- Janoshik Analytical
- Assay date
- 10 Dec 2024
- Submitted
- 11 Dec 2024
- Quarter
- 2024-Q4
- Submitter
- import_hold
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 99.49 | % area | ≥ 98.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.51 | % area | ≤ 1.5 | PASS |
| Largest single impurity | RP-HPLC — C-terminal free acid (+1 Da) | 0.31 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 639.3856 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 639.3855 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -0.2 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 89.65 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.19 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 23.77 | mg | 20 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 21.200 | mg | 20 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 106.0 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 3.69 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 6.07 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.59 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White cake, partial shrinkage from vial wall | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 4.87 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 8.91 | min | 8.94 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.08 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 67,715 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Arg1]-epimer | 1.28 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | SS-31 (Elamipretide) — main peak | 8.91 | 4,835,522 | 99.49 | — |
| 2 | C-terminal free acid (+1 Da) | 9.11 | 15,067 | 0.31 | +0.984 |
| 3 | des-Dmt (−193 Da) | 8.19 | 3,888 | 0.08 | -193.110 |
| 4 | [D-Arg1]-epimer | 8.73 | 2,916 | 0.06 | 0.000 |
| 5 | acetyl adduct (+42 Da) | 9.45 | 2,916 | 0.06 | +42.011 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 639.3856 Da, computed from C32H49N9O5. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 2+ | 320.7001 | 320.7000 | -0.0001 | 54.0 |
| 1+ | 640.3929 | 640.3928 | -0.0001 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 3.69 |
| Counter-ion (acetate) | ion chromatography | 6.07 |
| Residual solvent + inorganic residue | estimated | 0.59 |
| Total peptide content | by difference | 89.65 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.90 | 99.49 | divergence -0.01 pp vs batch median |
| Total impurities (% area) | 0.10 | 0.51 | |
| Largest single impurity (% area) | 0.06 | 0.31 | |
| Water (%) | 1.8 | 3.69 | |
| Counter-ion (%) | 9.4 | 6.07 | |
| Peptide content (%w/w) | 88.2 | 89.65 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → third-party forwarder (8 d) → laboratory (courier, cold pack, 12 d) → assay.
- Assay date
- 10 Dec 2024
- Submitted to the index
- 11 Dec 2024
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations 3
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot HOMO-2410-K5866 n=10
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2024-004792 | HOMO-2410-K5866 | Janoshik | 2024-Q4 | 99.66 | 3.89 | 97.8 | Buyer-sourced | 0 | PASS |
| AX-2024-004793 | HOMO-2410-K5866 | Janoshik | 2024-Q4 | 99.91 | 3.45 | 105.2 | Buyer-sourced | 0 | PASS |
| AX-2025-019860 | HOMO-2410-K5866 | Janoshik | 2024-Q4 | 99.91 | 3.34 | 92.2 | Buyer-sourced | 0 | PASS |
| AX-2024-004794 | HOMO-2410-K5866 | Janoshik | 2024-Q4 | 99.66 | 3.94 | 93.6 | Buyer-sourced | 0 | PASS |
| AX-2025-019861 | HOMO-2410-K5866 | Medutest | 2024-Q4 | 99.93 | 3.33 | — | Buyer-sourced | 0 | PASS |
| AX-2024-004795 | HOMO-2410-K5866 | PeptideMeter | 2024-Q4 | 99.93 | 4.34 | 90.0 | Laboratory-retained | 0 | PASS |
| AX-2024-004796 | HOMO-2410-K5866 | Medutest | 2024-Q4 | 99.93 | 3.39 | — | Buyer-sourced | 0 | PASS |
| AX-2024-004797 | HOMO-2410-K5866 | Medutest | 2024-Q4 | 99.93 | 3.37 | 90.3 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-019862 | HOMO-2410-K5866 | PeptideMeter | 2024-Q4 | 99.71 | 3.44 | 106.1 | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042222 | TFC | TFC-2607-R9099 | VendorInvestigate | 2026-Q3 | 99.46 | 5.41 | 102.6 | Buyer-sourced | 0 | PASS |
| AX-2026-042492 | Homopeptide | HOMO-2604-D5484 | Medutest | 2026-Q3 | 99.93 | 2.40 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042226 | TFC | TFC-2607-R9099 | Janoshik | 2026-Q3 | 99.62 | 5.47 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042491 | Homopeptide | HOMO-2604-D5484 | Kestrel | 2026-Q3 | 99.93 | 3.24 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042495 | Homopeptide | HOMO-2604-D5484 | PeptideMeter | 2026-Q3 | 99.93 | 3.22 | 105.9 | Supplier-supplied | 0 | PASS |
| AX-2026-042220 | TFC | TFC-2607-R9099 | Janoshik | 2026-Q3 | 99.83 | 4.90 | 105.2 | Buyer-sourced | 0 | PASS |
| AX-2026-042344 | TFC | TFC-2604-Y3208 | Janoshik | 2026-Q3 | 99.68 | 3.43 | 95.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042494 | Homopeptide | HOMO-2604-D5484 | Kestrel | 2026-Q3 | 99.93 | 2.69 | 96.0 | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042437 | Retatrutide | HOMO-2605-V4718 | Nordanalyt | 2026-Q3 | 98.68 | 3.67 | 102.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042424 | Semaglutide | HOMO-2604-X3806 | PeptideMeter | 2026-Q3 | 98.85 | 4.87 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-042503 | IGF-1 LR3 | HOMO-2607-P5131 | Janoshik | 2026-Q3 | 99.36 | 5.99 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042492 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Medutest | 2026-Q3 | 99.93 | 2.40 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042491 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Kestrel | 2026-Q3 | 99.93 | 3.24 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042473 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.01 | 5.00 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042441 | Retatrutide | HOMO-2605-V4718 | Medutest | 2026-Q3 | 98.93 | 4.22 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042474 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.18 | 5.44 | — | Buyer-sourced | 0 | PASS |